A trial of AZD0424 for advanced solid tumours

Cancer type:

All cancer types

Status:

Results

Phase:

Phase 1

This trial looked at AZD0424 for people with solid tumours that continued to grow despite other treatments, or for which no standard treatment was available.

A solid tumour Open a glossary item is any type of cancer apart from those of the blood or lymphatic system such as:

leukaemia
lymphoma

Cancer Research UK supported this trial.

More about this trial

AZD0424 is a targeted cancer drug. It works by slowing down or stopping the activity of proteins called Src and ABL1. These proteins help cells to grow.

In this trial, doctors wanted to see if AZD0424 was able to stop cancer cells from growing. This was the first time AZD0424 was given to people.

The main aims of this trial were to:

find out how well AZD0424 works as a treatment
find the highest dose of AZD0424 which can be given safely
learn more about the side effects and what happens to the drug in the body

Summary of results

The research team concluded that AZD0424 does not help people with advanced solid tumours.

This was a phase 1 trial. 43 people with advanced solid cancer took part. There were 17 people with advanced bowel cancer and 26 people with advanced cancer of one of these cancers:

lung
pancreas
anus
bile duct
cervix
breast

Everyone had AZD0424 capsules every day, once a day. The dose people had depended on part of the trial they joined. The first few people that took part had a small dose, and the next few people had a higher dose.

People took AZD0424 for as long as their cancer stayed the same and didn’t get worse. When their cancer got worse (disease progression Open a glossary item ), they stopped taking AZD0424.

The trial team had results for 41 people that had treatment. They found that in:

7 people (around 17%) the cancer stayed the same (stable disease )
34 people (around 83%) the cancer got worse (disease progression)

There was no response to treatment. This means that the AZD0424 treatment didn’t shrink the cancer.

The research team looked at the average length of time people lived without signs of their cancer getting worse. They found it was around 42 days.

The team also looked at the most common side effects people had. They were:

feeling or being sick
tiredness (fatigue)
loss of appetite (anorexia)
hair loss
constipation
low levels of phosphate in the blood

The team found that people who took a higher dose of AZD0424 had worse side effects.

So, the trial team concluded that AZD0424 does not help people with advanced solid tumours. They think no further research using this drug should be done in people with advanced solid tumours.

We have based this summary on information from the research team. As far as we are aware, the information they sent us has not been reviewed independently (peer reviewed Open a glossary item ) or published in a medical journal yet. The figures we quote above were provided by the research team. We have not analysed the data ourselves.